Brief: InflaRx Receives IND Approval From FDA To Start Phase II Clinical Trial Of IFX-1
28/06/2018 12:34
June 28 (Reuters) - Inflarx NV IFRX.O :
* INFLARX RECEIVES IND APPROVAL FROM THE FDA TO START ITS
PHASE II
CLINICAL TRIAL OF IFX-1 IN ANCA-ASSOCIATED VASCULITIS
* INFLARX NV - OPEN IND WILL ALLOW INFLARX TO START PLANNED
PHASE
II STUDY TO DETERMINE SAFETY AND EFFICACY OF IFX-1
Source text for Eikon: ID:nGNX7McrDw
Further company coverage: IFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum